275 related articles for article (PubMed ID: 28002800)
1. Sprouty2 correlates with favorable prognosis of gastric adenocarcinoma via suppressing FGFR2-induced ERK phosphorylation and cancer progression.
Xu Y; Yang X; Li Z; Li S; Guo S; Ismail S; Liu H; Huang Z; Zhang Z; Chen Y; Sun Q
Oncotarget; 2017 Jan; 8(3):4888-4900. PubMed ID: 28002800
[TBL] [Abstract][Full Text] [Related]
2. Sprouty2 suppresses progression and correlates to favourable prognosis of intrahepatic cholangiocarcinoma via antagonizing FGFR2 signalling.
Xu YF; Liu HD; Liu ZL; Pan C; Yang XQ; Ning SL; Zhang ZL; Guo S; Yu JM
J Cell Mol Med; 2018 Nov; 22(11):5596-5606. PubMed ID: 30160357
[TBL] [Abstract][Full Text] [Related]
3. Twist1 correlates with poor differentiation and progression in gastric adenocarcinoma via elevation of FGFR2 expression.
Zhu DY; Guo QS; Li YL; Cui B; Guo J; Liu JX; Li P
World J Gastroenterol; 2014 Dec; 20(48):18306-15. PubMed ID: 25561797
[TBL] [Abstract][Full Text] [Related]
4. Sprouty4 correlates with favorable prognosis in perihilar cholangiocarcinoma by blocking the FGFR-ERK signaling pathway and arresting the cell cycle.
Qiu B; Chen T; Sun R; Liu Z; Zhang X; Li Z; Xu Y; Zhang Z
EBioMedicine; 2019 Dec; 50():166-177. PubMed ID: 31761616
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of microRNA‑27b contributes to the migration and invasion of gastric cancer cells via the inhibition of sprouty2‑mediated ERK signaling.
Jiang J; Yi B; Qin C; Ding S; Cao W
Mol Med Rep; 2016 Mar; 13(3):2267-72. PubMed ID: 26781754
[TBL] [Abstract][Full Text] [Related]
6. Sprouty2 inhibits amphiregulin-induced down-regulation of E-cadherin and cell invasion in human ovarian cancer cells.
Cheng JC; Chang HM; Xiong S; So WK; Leung PC
Oncotarget; 2016 Dec; 7(49):81645-81660. PubMed ID: 27835572
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma.
Tokunaga R; Imamura Y; Nakamura K; Ishimoto T; Nakagawa S; Miyake K; Nakaji Y; Tsuda Y; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Saeki H; Yoshida N; Oki E; Watanabe M; Oda Y; Bass AJ; Maehara Y; Baba H
Oncotarget; 2016 Apr; 7(15):19748-61. PubMed ID: 26933914
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.
Sutterlüty H; Mayer CE; Setinek U; Attems J; Ovtcharov S; Mikula M; Mikulits W; Micksche M; Berger W
Mol Cancer Res; 2007 May; 5(5):509-20. PubMed ID: 17510316
[TBL] [Abstract][Full Text] [Related]
9. Sprouty 2 protein, but not Sprouty 4, is an independent prognostic biomarker for human epithelial ovarian cancer.
Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
Int J Cancer; 2015 Aug; 137(3):560-70. PubMed ID: 25630587
[TBL] [Abstract][Full Text] [Related]
10. Spry1 and Spry2 are necessary for eyelid closure.
Kuracha MR; Siefker E; Licht JD; Govindarajan V
Dev Biol; 2013 Nov; 383(2):227-38. PubMed ID: 24055172
[TBL] [Abstract][Full Text] [Related]
11. Sprouty2 enhances the tumorigenic potential of glioblastoma cells.
Park JW; Wollmann G; Urbiola C; Fogli B; Florio T; Geley S; Klimaschewski L
Neuro Oncol; 2018 Jul; 20(8):1044-1054. PubMed ID: 29635363
[TBL] [Abstract][Full Text] [Related]
12. FGFR2 Promotes Gastric Cancer Progression by Inhibiting the Expression of Thrombospondin4 via PI3K-Akt-Mtor Pathway.
Huang T; Liu D; Wang Y; Li P; Sun L; Xiong H; Dai Y; Zou M; Yuan X; Qiu H
Cell Physiol Biochem; 2018; 50(4):1332-1345. PubMed ID: 30355943
[TBL] [Abstract][Full Text] [Related]
13. FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential.
Zhang J; Wong CC; Leung KT; Wu F; Zhou Y; Tong JHM; Chan RCK; Li H; Wang Y; Yan H; Liu L; Wu WKK; Chan MWY; Cheng ASL; Yu J; Wong N; Lo KW; To KF; Kang W
Oncogene; 2020 Oct; 39(43):6647-6663. PubMed ID: 32934314
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of L1CAM is associated with tumor progression and prognosis via ERK signaling in gastric cancer.
Ito T; Yamada S; Tanaka C; Ito S; Murai T; Kobayashi D; Fujii T; Nakayama G; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Kodera Y
Ann Surg Oncol; 2014 Feb; 21(2):560-8. PubMed ID: 24046108
[TBL] [Abstract][Full Text] [Related]
15. Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL.
Shukla A; Rai K; Shukla V; Chaturvedi NK; Bociek RG; Pirruccello SJ; Band H; Lu R; Joshi SS
Blood; 2016 May; 127(19):2310-21. PubMed ID: 26809508
[TBL] [Abstract][Full Text] [Related]
16. Expression of Fibroblast Growth Factor 10 Is Correlated with Poor Prognosis in Gastric Adenocarcinoma.
Sun Q; Lin P; Zhang J; Li X; Yang L; Huang J; Zhou Z; Liu P; Liu N
Tohoku J Exp Med; 2015 Aug; 236(4):311-8. PubMed ID: 26268776
[TBL] [Abstract][Full Text] [Related]
17. SPROUTY2 is a β-catenin and FOXO3a target gene indicative of poor prognosis in colon cancer.
Ordóñez-Morán P; Irmisch A; Barbáchano A; Chicote I; Tenbaum S; Landolfi S; Tabernero J; Huelsken J; Muñoz A; Pálmer HG
Oncogene; 2014 Apr; 33(15):1975-85. PubMed ID: 23624922
[TBL] [Abstract][Full Text] [Related]
18. Sprouty2 regulates proliferation and survival of multiple myeloma by inhibiting activation of the ERK1/2 pathway in vitro and in vivo.
Yao Y; Luo J; Bian Y; Sun Y; Shi M; Xia D; Niu M; Zhao K; Zeng L; Chen W; Li Z; Xu K
Exp Hematol; 2016 Jun; 44(6):474-482.e2. PubMed ID: 27016275
[TBL] [Abstract][Full Text] [Related]
19. Dual role of sprouty2 as an inhibitor of RAS/ERK-driven proliferation and a promoter of cancer invasion in KRAS wild-type colorectal cancer.
Lee CT; Chu CA; Wang YM; Wang YW; Chen YL; Ho CL; Yeh YM; Lin PC; Lin BW; Chen PC; Chen SH; Chan RH; Chang C; Chow NH
Mol Carcinog; 2023 Jul; 62(7):951-962. PubMed ID: 37014154
[TBL] [Abstract][Full Text] [Related]
20. A reciprocal regulatory circuit between CD44 and FGFR2 via c-myc controls gastric cancer cell growth.
Park J; Kim SY; Kim HJ; Kim KM; Choi EY; Kang MS
Oncotarget; 2016 May; 7(19):28670-83. PubMed ID: 27107424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
